2072 related articles for article (PubMed ID: 17371468)
21. Insulin resistance is not strictly associated with energy intake or dietary macronutrient composition in women with polycystic ovary syndrome.
Toscani MK; Mario FM; Radavelli-Bagatini S; Spritzer PM
Nutr Res; 2011 Feb; 31(2):97-103. PubMed ID: 21419313
[TBL] [Abstract][Full Text] [Related]
22. Prevalence of the metabolic syndrome in German women with polycystic ovary syndrome.
Hahn S; Tan S; Sack S; Kimmig R; Quadbeck B; Mann K; Janssen OE
Exp Clin Endocrinol Diabetes; 2007 Feb; 115(2):130-5. PubMed ID: 17318774
[TBL] [Abstract][Full Text] [Related]
23. [The effects of hyperinsulinmia and insulin-like growth factor-1 on hyperandrogenism in polycystic ovarian syndrome].
Liang X; Zhuang G; Fan Q
Zhonghua Yi Xue Za Zhi; 1997 Apr; 77(4):266-9. PubMed ID: 9596926
[TBL] [Abstract][Full Text] [Related]
24. The metabolic syndrome in young Korean women with polycystic ovary syndrome.
Park HR; Choi Y; Lee HJ; Oh JY; Hong YS; Sung YA
Diabetes Res Clin Pract; 2007 Sep; 77 Suppl 1():S243-6. PubMed ID: 17610984
[TBL] [Abstract][Full Text] [Related]
25. Glucose intolerance in Japanese patients with polycystic ovary syndrome.
Kurioka H; Takahashi K; Miyazaki K
Arch Gynecol Obstet; 2007 Mar; 275(3):169-73. PubMed ID: 16972071
[TBL] [Abstract][Full Text] [Related]
26. Phenotypic expression, body mass index and insulin resistance in relation to LH levels in women with polycystic ovary syndrome.
Katsikis I; Karkanaki A; Misichronis G; Delkos D; Kandaraki EA; Panidis D
Eur J Obstet Gynecol Reprod Biol; 2011 Jun; 156(2):181-5. PubMed ID: 21353371
[TBL] [Abstract][Full Text] [Related]
27. The association of bone mineral density with insulin resistance in patients with polycystic ovary syndrome.
Noyan V; Yucel A; Sagsoz N
Eur J Obstet Gynecol Reprod Biol; 2004 Aug; 115(2):200-5. PubMed ID: 15262356
[TBL] [Abstract][Full Text] [Related]
28. Serum Fetuin-A levels, insulin resistance and oxidative stress in women with polycystic ovary syndrome.
Enli Y; Fenkci SM; Fenkci V; Oztekin O
Gynecol Endocrinol; 2013 Dec; 29(12):1036-9. PubMed ID: 23961784
[TBL] [Abstract][Full Text] [Related]
29. Clinical, metabolic and endocrine parameters in response to metformin in obese women with polycystic ovary syndrome: a randomized, double-blind and placebo-controlled trial.
Chou KH; von Eye Corleta H; Capp E; Spritzer PM
Horm Metab Res; 2003 Feb; 35(2):86-91. PubMed ID: 12734787
[TBL] [Abstract][Full Text] [Related]
30. Effects of metformin therapy on hyperandrogenism in women with polycystic ovarian syndrome.
Kazerooni T; Dehghan-Kooshkghazi M
Gynecol Endocrinol; 2003 Feb; 17(1):51-6. PubMed ID: 12724019
[TBL] [Abstract][Full Text] [Related]
31. Is the plasma anti-Müllerian hormone (AMH) level associated with body weight and metabolic, and hormonal disturbances in women with and without polycystic ovary syndrome?
Skałba P; Cygal A; Madej P; Dąbkowska-Huć A; Sikora J; Martirosian G; Romanik M; Olszanecka-Glinianowicz M
Eur J Obstet Gynecol Reprod Biol; 2011 Oct; 158(2):254-9. PubMed ID: 21752527
[TBL] [Abstract][Full Text] [Related]
32. Influence of body mass index on measured and calculated androgen parameters in adult women with Hirsutism and PCOS.
Cupisti S; Dittrich R; Binder H; Kajaia N; Hoffmann I; Maltaris T; Beckmann MW; Mueller A
Exp Clin Endocrinol Diabetes; 2007 Jun; 115(6):380-6. PubMed ID: 17701884
[TBL] [Abstract][Full Text] [Related]
33. Specific dermatologic features of the polycystic ovary syndrome and its association with biochemical markers of the metabolic syndrome and hyperandrogenism.
Ozdemir S; Ozdemir M; Görkemli H; Kiyici A; Bodur S
Acta Obstet Gynecol Scand; 2010; 89(2):199-204. PubMed ID: 19900078
[TBL] [Abstract][Full Text] [Related]
34. Serum leptin levels correlate with clinical and biochemical indices of insulin resistance in women with polycystic ovary syndrome.
Pehlivanov B; Mitkov M
Eur J Contracept Reprod Health Care; 2009 Apr; 14(2):153-9. PubMed ID: 19340711
[TBL] [Abstract][Full Text] [Related]
35. Evaluation of insulin resistance and metabolic syndrome in patients with polycystic ovary syndrome.
Lankarani M; Valizadeh N; Heshmat R; Peimani M; Sohrabvand F
Gynecol Endocrinol; 2009 Aug; 25(8):504-7. PubMed ID: 19499403
[TBL] [Abstract][Full Text] [Related]
36. Risk of metabolic complications in the new PCOS phenotypes based on the Rotterdam criteria.
Shroff R; Syrop CH; Davis W; Van Voorhis BJ; Dokras A
Fertil Steril; 2007 Nov; 88(5):1389-95. PubMed ID: 17462641
[TBL] [Abstract][Full Text] [Related]
37. Increased serum advanced glycation end-products is a distinct finding in lean women with polycystic ovary syndrome (PCOS).
Diamanti-Kandarakis E; Katsikis I; Piperi C; Kandaraki E; Piouka A; Papavassiliou AG; Panidis D
Clin Endocrinol (Oxf); 2008 Oct; 69(4):634-41. PubMed ID: 18363886
[TBL] [Abstract][Full Text] [Related]
38. Low sex hormone-binding globulin is associated with low high-density lipoprotein cholesterol and metabolic syndrome in women with PCOS.
Chen MJ; Yang WS; Yang JH; Hsiao CK; Yang YS; Ho HN
Hum Reprod; 2006 Sep; 21(9):2266-71. PubMed ID: 16757555
[TBL] [Abstract][Full Text] [Related]
39. Increased androgen bioavailability is associated with non-alcoholic fatty liver disease in women with polycystic ovary syndrome.
Vassilatou E; Lafoyianni S; Vryonidou A; Ioannidis D; Kosma L; Katsoulis K; Papavassiliou E; Tzavara I
Hum Reprod; 2010 Jan; 25(1):212-20. PubMed ID: 19887498
[TBL] [Abstract][Full Text] [Related]
40. Premature androgenic alopecia and insulin resistance. Male equivalent of polycystic ovary syndrome?
Starka L; Duskova M; Cermakova I; Vrbiková J; Hill M
Endocr Regul; 2005 Dec; 39(4):127-31. PubMed ID: 16552990
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
